474645-98-2

Usage

Chemical Properties

White Solid

Uses

Torcetrapib intermediate.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 124-63-0 methanesulfonyl chloride 
• 150736-71-3 tert-butyl (R)-(1-hydroxybutan-2-yl)carbamate 

Downstream Products

• 198493-28-6 (R)-N-tert-butyloxycarbonyl-3-aminopentanenitrile 
• 198493-29-7 ((R)-1-ethyl-3-oxo-propyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Design of Selenium-Based Chiral Chemical Probes for Simultaneous Enantio- and Chemosensing of Chiral Carboxylic Acids with Remote Stereogenic Centers by NMR Spectroscopy

Selenium-based enantiopure chiral chemical probes have been designed in a modular way starting from available amino alcohols. The probes developed were found to be efficient in chemoselective interaction with carboxylic functions of chiral substrates leading to diastereomeric amide formation and in sensing α-, β-, and remote (up to seven bonds away from the carboxylic group) chiral centers by using77Se NMR spectroscopy. As a result, it was possible to determine the enantiomeric ratio of structurally diverse individual chiral acids including polyfunctional compounds and drugs with high accuracy. An approach to analyzing the crude reaction mixtures has been successfully developed by using bifunctional selenium- and fluorine-containing chiral probes. More importantly, it was revealed that, based on the77Se NMR data obtained, it is possible to obtain primary information about the location and nature of the substituents at the chiral center (chemo- and enantiosensing), which can simplify the structural elucidation of complex compounds. The derivatization procedure takes as little as 5 min and can be performed directly in an NMR tube followed by NMR measurements without any isolation and purification steps.

AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

Asymmetric synthesis of the cholesteryl ester transfer protein inhibitor torcetrapib

Previously our group reported synthetic efforts used to synthesize kilogram quantities of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, 1, via a mid-stage resolution. This account describes research conducted to develop an asymmetri

Synthesis of homochiral N-Boc-β-aminoaldehydes from N-Boc-β-aminonitriles

Enantiopure N-Boc-β-aminoaldehydes are efficiently prepared in good yields from N-Boc-β-aminonitriles by reduction of the nitrile function with diisobutylaluminium hydride (DIBAL-H) - Keywords: β-aminoaldehyde; β-aminonitrile; α-aminoacid; homochiral; enantiomeric excess; reduction; DIBAL-H

Asymmetric syntheses of (R)- and (S)-2-aminobutanesulfonic acid and their 3,3-dimethylderivatives

(R)- and (S)-2-aminobutanesulfonic acid, 3a and 3b, and (R)- and (S)-2-amino-3,3-dimethylbutanesulfonic acid, 4a and 4b, were synthesized from the corresponding N-Boc protected β-amino alcohols in good yields and high enantiomeric purities (> 99% ee).